EUCTR2015-001535-21-GR进行中（未招募）1 期
A Randomized, Multi-Center, Phase 2 Study to Evaluate Safety and Efficacy of Subcutaneous Injections of RG-101 in Combination with Oral Agents in Treatment Naïve, Genotype 1 and 4, Chronic Hepatitis C Patients
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 54
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Both males and females of age 18 to 65 (inclusive) infected with one of the HCV genotype 1 or 4;
- •2. BMI: 18.0 – 35.0 kg/m2;
- •[BMI (kg/m2) = Body weight (kg) ÷ Height2 (m2)];
- •3. Clinical and laboratory findings consistent with a clinical diagnosis of Chronic Hepatitis C (CHC), including:
- •Previous documentation of positive HCV serology (HCV antibody or HCV RNA) at least 24 weeks prior to enrollment,
- •Positive HCV serology (HCV antibody or HCV RNA) less than 24 weeks with a prior remote risk factor (more than 24 weeks prior to Screening) for the acquisition of hepatitis C
- •Serum HCV RNA = 375,000 copies/mL or = 75,000 IU/mL at Screening;
- •4. HCV treatment-naïve;
- •5. Screening hematology, clinical chemistries, coagulation and urinalysis are not clinically significant and the following criteria are met:
- •Platelets >100x109/L
- •Total white blood cells >3.0x109/L and absolute neutrophil count >1.5x109/L
- •Hemoglobin >10.95 g/dL for females and >11.92 g/dL for males
- •Total and direct bilirubin within normal limits (except for clearly documented Gilbert’s Syndrome)
- •ALAT < 5x ULN
- •Serum creatinine within normal limits or increased up to 1,5 ULN and estimated creatinine clearance rate as calculated by the Cockcroft-Gault formula > 60 mL/min
- •6. All women of childbearing potential must have a negative serum pregnancy test at Screening. They should be using or willing to use a highly effective method of birth control: diaphragm, condom (by the partner), copper intrauterine device (or hormonal), sponge, or spermicide, and hormonal contraceptives. Appropriate hormonal contraceptives will include any registered and marketed contraceptive agent that contains an estrogen and/or a progestational agent (including oral, s.c., intrauterine, or intramuscular agents). Reliable contraception should be maintained from the Screening, throughout the whole study (W53);
- •7. Male subjects must agree to use birth control (condoms) from the time of dosing until 90 days after the Treatment Period; male subjects who are surgically sterile need not employ a method of contraception;
- •8. Negative results on the screening alcohol saliva test. Subjects should be able and willing to limit the alcohol intake to a maximum of 5 units per week during the whole study period (1 unit of alcohol equals approximately 250 mL of beer, 100 mL of wine or 35 mL of spirits);
- •9. Negative results on the following screening laboratory tests: urine drug screen [opiates, cocaine, heroin, amphetamines (including ecstasy), barbiturates, benzodiazepines, tricyclic antidepressants; exceptions are cannabinoids and methadone], HBsAg, and HIV antibody;
- •10. Willingness to sign the ICF and obvious ability (mental and physical) to adhere to all study procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 53
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 1
排除标准
- •1. Other known cause of liver disease except for CHC;
- •2. History or symptoms of decompensated liver disease: Child-Pugh Class B or C, including ascites, hepatic encephalopathy, esophageal variceal bleeding, fibrosis or other signs of hepatic insufficiency or portal hypertension;
- •3. History of hepatocellular carcinoma or current liver mass consistent with malignancy on imaging studies;
- •4. Serum alpha-fetoprotein (AFP) >50 ng/mL at Screening;
- •5. Concurrent clinically significant medical diagnosis (other than hepatitis C-related conditions) that would potentially interfere with the subjects study compliance or confound study results including but not limited to: cardiac disease (unstable angina, myocardial infarction, congestive heart failure, or ventricular arrhythmia); cancer; uncontrolled seizure disorder; esophageal bleeding; ascites; chronic infection other than HCV (e.g., tuberculosis); uncontrolled diabetes;
- •6. Fibrosis scan score > F4 at Screening or within past 6 months;
- •7. Concurrent social conditions (e.g., drugs, alcohol) which would potentially interfere with the subject’s study compliance;
- •8. Use of anticonvulsants, antimycobacterials, analeptics and herbal supplements that may interact with the bioavailability of the investigational product or oral DAA agents; or other alternative medicines that may have influence on the disease outcome;
- •9. Mental handicap or history of or current significant psychiatric disease (which might impair ability to provide informed consent);
- •10. Clinically significant illness within 30 days prior to Screening;
- •11. Have used an investigational drug or has participated in an investigational study with a licensed drug within 30 days or 5 half-lives, whichever is longer, prior to study drug administration;
- •12. History of relevant drug and/or food allergies;
- •13. Nursing females;
- •14. Any surgical procedure requiring general anesthesia planned to occur during the study period;
- •15. Donation of more than 500 mL of blood within 60 days prior to drug administration. Donation of more than 1.5 liters of blood (for men) / more than 1.0 liter of blood (for women) in the 10 months prior to Screening.
研究者
相似试验
进行中（未招募）
1 期
A clinical trial in patients with the liver disease caused by the hepatitis C virus for assessment of safety and efficacy of RG-101 injections (test product) given in combination with other registered drugs that are to be taken by mouthEUCTR2015-001535-21-HURegulus Therapeutics Inc.54
尚未招募
2 期
A Phase 2, Multicenter, Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of ST-617 for the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for Head and Neck CancerOral MucositisHead and Neck CancerCancer - Head and neckOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonACTRN12620000540910PSI CRO Australia Pty. Ltd.110
进行中（未招募）
1 期
Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic TherapyEUCTR2024-000203-67-Outside-EU/EEAKadmon Corporation, LLC
进行中（未招募）
不适用
A Randomized, Multi-Center, Phase II Study to Investigate the Safety and Efficacy of SDX-101 (R-etodolac) in Combination with Chlorambucil, and that of Chlorambucil alone, in Patients with Chronic Lymphocytic Leukemia (CLL) -Chronic Lymphocytic Leukemia (CLL)EUCTR2004-000440-24-SECephalon UK Limited80
未知
2 期
Efficacy and Safety Study of CNTO 2476 in Participants with Visual Acuity Impairment Associated with Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD)JPRN-jRCT1080223359Janssen Pharmaceutical K.K.60